Using Genetic Polymorphisms to Predict the Efficacy and Toxicity - A Gastric Adenocarcinoma Study
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-comparative phase II study of sequential capecitabine plus
oxaliplatin followed by docetaxel plus capecitabine in patients with unresectable gastric
adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Mackay Memorial Hospital National Cheng-Kung University Hospital Taipei Veterans General Hospital, Taiwan Tri-Service General Hospital